Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. - Wikidata - wikimedia - TriplyDB

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.

http://www.wikidata.org/entity/Q33942951

about

Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.Microtubule-binding agents: a dynamic field of cancer therapeutics.Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth 2-Methoxyestradiol ameliorates glucose tolerance with the increase in β-cell mass in db/db mice.An image-based, high-throughput screening assay for molecules that induce excess DNA replication in human cancer cells Anticancer drug 2-methoxyestradiol protects against renal ischemia/reperfusion injury by reducing inflammatory cytokines expression A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.Intra-Laboratory Pre-Validation of a Human Cell Based in vitro Angiogenesis Assay for Testing Angiogenesis Modulators.Novel estradiol analogue induces apoptosis and autophagy in esophageal carcinoma cells.A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.Mitochondrial peroxiredoxin III is a potential target for cancer therapy Induction of the intrinsic apoptotic pathway via a new antimitotic agent in an esophageal carcinoma cell line The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia.Ezrin, radixin, and moesin are phosphorylated in response to 2-methoxyestradiol and modulate endothelial hyperpermeability.2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model.Molecular crosstalk between apoptosis and autophagy induced by a novel 2-methoxyestradiol analogue in cervical adenocarcinoma cells.Critical role of cyclin B1/Cdc2 up-regulation in the induction of mitotic prometaphase arrest in human breast cancer cells treated with 2-methoxyestradiol.Applications of nanoparticles in the detection and treatment of kidney diseases The Bone Sparing Effects of 2-Methoxyestradiol Are Mediated via Estrogen Receptor-α in Male Mice.Nanoparticles containing insoluble drug for cancer therapy.Microtubules as antifungal and antiparasitic drug targets.Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.2-methoxyestradiol in the pathophysiology of endometriosis: focus on angiogenesis and therapeutic potential.Recent advancements in mechanical reduction methods: particulate systems.2-methoxyestradiol and disorders of female reproductive tissues.Amorphous solid dispersion technique for improved drug delivery: basics to clinical applications.Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia.Novel in silico-designed estradiol analogues are cytotoxic to a multidrug-resistant cell line at nanomolar concentrations.Hydrogel-PLGA delivery system prolongs 2-methoxyestradiol-mediated anti-tumor effects in osteosarcoma cells.2-Methoxyestradiol induced Bax phosphorylation and apoptosis in human retinoblastoma cells via p38 MAPK activation.2-Methoxyoestradiol inhibits glucose transport in rodent skeletal muscle.In vitro effects of an in silico-modelled 17β-estradiol derivative in combination with dichloroacetic acid on MCF-7 and MCF-12A cells.2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy.The in vitro effects of a novel estradiol analog on cell proliferation and morphology in human epithelial cervical carcinoma.Are estradiol metabolites involved in gynaecological carcinogenesis?Injectable delivery system of 2-methoxyestradiol for breast cancer therapy using biodegradable thermosensitive poly(organophosphazene) hydrogel.2-Methoxyestradiol Attenuates Testosterone-Induced Benign Prostate Hyperplasia in Rats through Inhibition of HIF-1/TGF-/Smad2 Axis

P2860

Q21142766-4E11B0C3-F306-42D7-8E62-E2CD02AD0E51 Q27690249-9167F9DE-20CE-414E-B921-24BD142770CC Q28547500-8CF6CE2B-A57A-4FFE-BB03-A2F902011001 Q33585615-05864B1D-5C7E-4D15-93DC-36313CF61847 Q33800817-18D3218D-275B-4B38-9508-87006D5041FD Q34116910-9E0862B6-A449-4A17-A0CA-4F41FC4B294B Q34587714-2BC3C9C5-79BA-47A2-A407-635FE90F9F1F Q34691671-44EFF556-E2B8-4CD1-9D8F-3269DBCA8209 Q35090804-3280500B-0BCD-499C-81D0-C7E591615A67 Q35100891-DCBA02AB-DD75-405A-BE2C-4DE2DB0BAE4E Q35100992-9B47EE09-2BEE-4947-9F8E-6F5688C5C479 Q35316783-18CECB48-708E-43A1-8AEF-83231D1C18F6 Q35536098-2C62935F-1B6C-4781-AE1C-85ED1F766AAB Q35563305-2907FF80-7CB6-46FC-BB7B-B441EBA819E4 Q35591704-EBF1D295-3943-47D8-97A0-8783C4172610 Q35684785-362BD8EC-DFB7-4E68-985C-E39E9B1FB1A1 Q36485290-F99170F5-77A6-4538-83E3-496E5BA43D92 Q36509772-7FE18889-48DE-4993-AADF-FACF30D56477 Q37155076-46B8AEC1-7B99-4F7D-B74E-1E380BD614CF Q37183449-214A10DC-0D81-4A30-A917-CC87CAA76E35 Q37298541-D99A8BFC-C558-4359-A109-C77FDB804D66 Q37378634-E1C46B6A-5081-4DE9-911F-1785B48621F4 Q37693046-4C106785-5A72-4B16-B85F-619485F37CC6 Q37825895-C93203BE-7944-466C-A225-A94402328E2A Q38003390-BF00D6E9-848E-46DD-BC6A-C26143A12BC6 Q38033141-B3D16B4B-B213-4AC4-8C6B-DC8D88838BF6 Q38132471-8D3E50A6-FD27-4604-90F7-5DA83B902DC4 Q38206991-9645F17F-5EF1-4934-B536-280162EDE35C Q38573658-A6F43023-F9C7-410B-939A-56DAAB66268D Q38821162-73BB4E0C-8FA2-4472-8ECE-E990DFBBD406 Q38924636-B438BEDF-B807-42B9-B28A-3EDB45B0DF5F Q39203583-024F78BC-75F3-4C0E-BE2B-AF0CEE35329E Q39504485-16F76ED2-0E71-4F77-8718-EEDC89CE425C Q43062321-72D220FC-DF79-4076-8FAD-0496C6C7C0C9 Q46449939-8099FDEE-86CE-46DF-B2AC-91DCF926A83E Q49185697-8D2AA088-6BAF-40F9-BD58-3E0DA6D52698 Q51732181-E5C95DA2-14D5-4F9C-9BDF-F7296B15E371 Q53303261-A2097279-C1F5-4382-9376-2216C30EA40D Q53314145-370A68AC-FA77-4F47-B79B-BEC43D0177D1 Q58805809-DEC75923-98C0-48DC-84A9-46BB106C4496

P2860

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.

http://www.wikidata.org/entity/Q33942951

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase I trial of 2-methoxyestr ...... n advanced solid malignancies.

@ast

Phase I trial of 2-methoxyestr ...... n advanced solid malignancies.

@en

type

label

Phase I trial of 2-methoxyestr ...... n advanced solid malignancies.

@ast

Phase I trial of 2-methoxyestr ...... n advanced solid malignancies.

@en

prefLabel

Phase I trial of 2-methoxyestr ...... n advanced solid malignancies.

@ast

Phase I trial of 2-methoxyestr ...... n advanced solid malignancies.

@en

P1433

Q33942951-580DBDF8-31EF-4CCF-B8A3-E76A3FFC62BB

P1476

Q33942951-C5076D48-D0E1-4299-B4BB-DC054C06CBFA

P2093

Q33942951-09E902BE-D8FF-4FFB-AF6B-B882989A8C75

Q33942951-97861467-75B3-4431-8544-F3D788AC810C

Q33942951-9F5D6E25-A095-4E3F-8940-E7D4F2B01DC6

Q33942951-A805D857-E5C5-4D0C-AE73-B59A788BE6D3

Q33942951-E1EEBDD4-579E-4134-8719-535C86A1639B

Q33942951-F501AA8A-CAB8-4820-B420-203F884B2190

Q33942951-F5347E70-A7BC-41C0-8130-148042D31F95

P2860

Q33942951-05FF7C6D-1946-406D-A8EB-5694C397D0BB

Q33942951-1F1D7AC2-BF3E-4021-8356-31A6682FA6C5

Q33942951-202AE53E-9655-4BCB-8297-AB562252B4BF

Q33942951-2A30BA10-7F31-461F-B2CE-AD5C0F65A933

Q33942951-2B04FD3D-C845-4CB7-8FAC-24D6F3CD3018

Q33942951-33D132F4-5635-485C-AD18-C38DEC7F7C0F

Q33942951-4A845E28-2E3B-440F-9BC2-2DAB0B8FE0BE

Q33942951-5C143218-B107-438B-B3C2-7F3CB6C56157

Q33942951-6087729A-9F75-4F04-A6AF-B1A7AF5EC4AE

Q33942951-8C05E1DB-63E6-41B9-9BA1-7D62429F5071

P304

Q33942951-C273DDEF-EECA-4ECA-8BFC-0419C22B4AD0

P31

Q33942951-0EA86340-302A-4C9C-80E7-94FA06DE8415

P356

Q33942951-449EA275-7BBF-404E-9C33-BED8819186DB

P407

Q33942951-185D562B-0805-4FE3-BBB4-95026ED7E988

P433

Q33942951-59234FA5-2D37-4912-8C5F-A4CA61A156F1

P478

Q33942951-CF282510-3BAE-4DF4-9D3A-5A4433D822FF

P50

Q33942951-3B8C7A36-B6F1-4FB7-8F49-6E2CE87D2F72

P577

Q33942951-EB53E112-4098-43D1-AF5F-80B91F0BB46A

P698

Q33942951-C5A99BDD-E056-4393-9805-CABAC43B7A13

P921

Q33942951-696C7117-E1F4-4E0C-B9F2-F07AAA1B7216

Q33942951-A68904E6-7E24-4146-8487-DCD6D26DA742

P932

Q33942951-B7CAFE6B-5633-456F-94F1-9F2A4171B73F

P356

1078-0432.CCR-08-1599

P1433

Clinical Cancer Research

P1476

Phase I trial of 2-methoxyestr ...... n advanced solid malignancies.

@en

P2093

Amye J Tevaarwerk

http://www.w3.org/2001/XMLSchema#string

Carolyn Sidor

http://www.w3.org/2001/XMLSchema#string

Check Quon

http://www.w3.org/2001/XMLSchema#string

Dona B Alberti

http://www.w3.org/2001/XMLSchema#string

Glenn Liu

http://www.w3.org/2001/XMLSchema#string

Jamie Arnott

http://www.w3.org/2001/XMLSchema#string

Kyle D Holen

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.

Mechanism of action of 2-methoxyestradiol: new developments.

The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice.

Serum concentration and urinary excretion of "classical" estrogens, catecholestrogens and 2-methoxyestrogens in normal human pregnancy.

2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression.

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth.

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer.

P304

1460-1465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1599

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19228747

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

2-methoxyestradiol

P932

2892631

http://www.w3.org/2001/XMLSchema#string